# Filing Detail

Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001628280-23-013213
Filing Date
2023-04-26
Accepted
2023-04-26 16:01:31
Documents
6

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 424B5 | innatepharma424b5april2023.htm | 424B5 | 896656
2 |  | image_01a.jpg | GRAPHIC | 15911
3 |  | image_0a.jpg | GRAPHIC | 36302
4 |  | innatepharmalogoa.jpg | GRAPHIC | 52807
5 |  | pipea.jpg | GRAPHIC | 166640
6 |  | prospectussummary1aa.jpg | GRAPHIC | 307265
| Complete submission text file | 0001628280-23-013213.txt |  | 1692015

Mailing Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009
Business Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009 33430303030
Innate Pharma SA (Filer) CIK: 0001598599 (see all company filings)

EIN.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-252074 | Film No.: 23849614
SIC: 2836 Biological Products, (No Diagnostic Substances)